Ginkgo Bioworks to Go Public in a $17.5 Billion Reverse Merger With Harry Sloan's SPAC, Cathie Wood's Ark and Bill Gates' Cascade Among Investors

May 11, 2021 8:57 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Biotech company Ginkgo Bioworks Inc. announced it is going public in a $17.5 billion merger with a special acquisition purpose company (SPAC) backed by the business executive Harry Sloan.

Ginkgo, which calls itself ‘the organism company,” utilizes advanced technology to program cells for a number of different uses. The company is set to merge with the blank-check company Soaring Eagle Acquisition Corp. (Nasdaq: SRNG), according to a regulatory filing Tuesday.

“Ginkgo’s platform makes it easier to program this code, and we are making this platform available to organizations working to solve our most pressing problems. From mRNA vaccines reaching people’s arms to combating climate change, the opportunity to work with programmed cells has never been more apparent. We are thrilled to partner with Arie as well as the team at Soaring Eagle to bring this vision to life,” said Jason Kelly, co-founder and CEO of Ginkgo Bioworks.

The deal involves a $775 private placement led by Baillie Gifford, Putnam Investments, and Morgan Stanley Investment Management’s Counterpoint Global arm. Other participants include Cathie Wood’s Ark Investment Management LLC, Bain Capital’s public equity unit, Bill Gates’s Cascade Investment LLC and T. Rowe Price Associates Inc.

“Ginkgo is not only a leader in this field, but its founders launched the modern practice of synthetic biology. There has never been a more critical time to employ Ginkgo’s technological achievements and efficiencies toward solving so many real-world problems—environment, food, and health to name a few. We’ve been so impressed with Jason and his co-founders’ sense of purpose and we believe that this team will be the ambassadors of these advances for decades to come,” Sloan commented.

Ginkgo will reach a valuation of $15 billion, before taking into account the proceeds secured by the SPAC and other investors. Soaring Eagle secured $1.73 billion including greenshoe shares in an IPO in February.

Instead of using zeros and ones, Gingko uses the four essential building blocks of DNA sequencing to program mammal, bacteria, and yeast cells to serve specific purposes. Last year, the organism company remodeled its technology and made it able to read and modify living cells in an effort to address the deficit of diagnostic testing.

The deal is expected to close in the third quarter of 2021, subject to the approval of the stockholders of both companies, and depending on certain regulatory approvals. Belldegrun will be joining Ginkgo’s board as a part of the agreement.

Ginkgo is a Boston-headquartered company founded in 2009 by a group of Massachusetts Institute of Technology graduate students and then-professor Tom Knight.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Mergers and Acquisitions, SPAC

Related Entities

Bill Gates, Morgan Stanley, Bain Capital, Baillie Gifford & Co., Putnam Investments, Cascade Investment, Definitive Agreement, IPO, ARK, SPAC